Safe and Effective Treatment of Chronic Pain

Chorda Pharma was founded to address the growing incidence of arthritis, diabetic neuropathy, sports injuries, and other ailments requiring long-term treatment to relieve pain. We are developing a pipeline of proprietary analgesics for managing chronic pain. Our medications are opioid-free, and offer safe and effective pain relief to millions of patients. Chorda's first drug is an over-the-counter (OTC) topical cream that will be available early in 2022.

web development

Growing Need for Non-Addictive Pain Relief

Arthritis is the number one cause of disability in America, with more than 54 million people afflicted. Common prescription medications such as corticosteroids and over the counter (OTC) treatments, including non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, are not considered safe for long-term treatment of pain. Finding safe alternatives to traditional OTC and prescription-based pain relievers, like opioids, is an industry priority. According to the U.S. Department of Health and Human Services, addiction to opioid pain relievers has contributed to a national public health emergency, with 10 million patients misusing prescription opioids in the past year and over 70,000 drug overdose deaths.

Testimonials

Chorda Announces Partnership with Carilion Clinic

Chorda Pharma is partnering with Carilion Clinic to develop, test, and market non-opioid medications to treat chronic pain. Chorda Pharma’s first analgesic medication is an OTC topical cream. Clinical trials will be performed at Carilion Clinic to demonstrate the tolerability of the proprietary drug.

Carilion Clinic is a not-for-profit health care organization serving more than one million people in Virginia’s Blue Ridge and Southwest Virginia regions. Headquartered in Roanoke, Carilion’s comprehensive hospital network, primary and specialty physician practices, and other complementary services deliver high-quality, patient-centered care close to home.


Download the full announcement.

Radio interview with CEO Victor Iannello on WFIR